40 Winks

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of 40 Winks

Quick Facts

Property Description
Active ingredient Diphenhydramine (hydrochloride)
Form Oral dosage form (Tablets or Capsules)
Pharmacological class First-generation Antihistamine (H1-receptor antagonist)
Common use Non-prescription sleep aid
Origin Synthetic compound

What Type of Medicine is 40 Winks and What Does it Contain?

40 Winks is an over-the-counter (OTC) medication classified pharmacologically as a first-generation antihistamine, intended primarily for sleep assistance. The active ingredient is Diphenhydramine (typically as the hydrochloride salt), a synthetic compound that functions as an H1-receptor antagonist. This formulation is distinctive because it harnesses the sedative property of Diphenhydramine, which is clinically recognized as a potent effect supported by established pharmacological studies. Unlike non-sedating antihistamines used for daytime allergies, the primary positioning of 40 Winks is centered solely on this sleep-inducing capability. It is presented as an oral dosage form, commonly as tablets or capsules, and contains this single active compound.

The General Purpose of 40 Winks and its Classification

The general therapeutic purpose of 40 Winks is to function as a temporary non-prescription sleep aid for adults dealing with minor difficulties in initiating sleep, such as during periods of temporary stress or travel-related disruption. This application is supported by regulatory standards, which regard Diphenhydramine as generally recognized as safe and effective (GRASE) for this specific nighttime purpose. The compound achieves its effect through CNS depressant activity, which slows alertness by blocking histamine receptors. This mechanism provides a reliable, verified means of encouraging the necessary state of drowsiness, thereby addressing the common problem of transient insomnia directly.

What side effects are possible with 40 Winks?

Possible Side Effects and Safety Information

The safety profile for 40 Winks, containing the first-generation antihistamine Diphenhydramine, is comprehensively documented by regulatory authorities, classifying potential adverse reactions by both frequency and the systems they affect.

Officially Classified Adverse Reactions

The most frequently reported side effects are directly related to the drug’s intended action and its anticholinergic properties. These reactions are grouped according to official regulatory classification standards:

Classification Examples of Documented Effects
Common Somnolence (drowsiness), fatigue, dry mouth, and headache.
Uncommon Dizziness, disturbance in attention, incoordination, and nausea.
Rare Blood dyscrasias and muscular twitching.

Adverse effects are also categorized by the physiological system involved, including Nervous System Disorders (e.g., sedation), Gastrointestinal Disorders, Eye Disorders (e.g., blurred vision), and Renal and Urinary Disorders (e.g., urinary retention).

Serious Reactions and Safety Constraints

Official labeling documents rare but clinically significant events classified as serious adverse reactions, which include certain types of hypersensitivity reactions (such as angioedema) and specific blood dyscrasias. Furthermore, the safety profile dictates specific constraints on use. The medicine is formally contraindicated in individuals with conditions like narrow-angle glaucoma and certain conditions that cause urinary retention.

Population-Specific Safety Notes

The regulatory profile highlights specific considerations for certain groups. Older adults are officially documented as being more susceptible to specific central nervous system effects, such as confusion and dizziness, and they have an increased risk of urinary retention. Safety notes also state that effects like drowsiness may be most prominent following initial use.

Overdose and Emergency Response

Official Regulatory Overdose Profile

The following information summarizes the official overdose descriptions for 40 Winks (Diphenhydramine) as documented in governmental regulatory sources.

Element Regulatory Summary
Documented Manifestations Initial signs may include profound somnolence, stupor, confusion, and deep sedation. Anticholinergic effects such as mydriasis (pupil dilation), dry mouth, urinary retention, and hyperthermia are also listed. Paradoxical excitation, including agitation and hallucinations, is specifically noted as a risk for pediatric patients.
Life-Threatening Outcomes Severe toxicity can escalate to serious cardiovascular events, including arrhythmias and cardiac collapse. Neurological complications documented in labeling include convulsions (seizures) and progression to profound coma or respiratory depression, with potential for death.
Population Considerations The elderly are specifically noted to be more susceptible to pronounced anticholinergic and CNS toxic effects, such as delirium and confusion.

Mandatory Emergency Action and Management

  • Seek immediate medical attention or contact emergency services immediately upon any suspected overdose or ingestion of excessive doses, as severe outcomes can develop rapidly.
  • The primary management approach in a healthcare setting is symptomatic and supportive treatment.
  • Continuous cardiorespiratory monitoring is often required due to the risk of severe cardiac events, and hospital observation must continue until the patient's condition is stable.
  • Official documents indicate that no specific antidote is known to counteract the effects of Diphenhydramine overdose. The need for urgent professional care is mandated due to the high-risk potential.

Therapeutic Uses of 40 Winks

The primary therapeutic domain for non-prescription sleep aids is applied across domains where additional symptomatic support is needed. This type of medication is intended for use as an aid for easing temporary difficulties sleeping in adults. The product is considered relevant in clinical settings that involve acute or unstable symptom patterns, which is often used during phases when symptoms become more noticeable.

The support helps address symptom clusters that may become intense or disruptive and is applied when symptoms create noticeable functional strain. The primary uses are commonly used across conditions presenting with acute episodes, helping address symptoms related to heightened physiological activity. This support contributes to easing the overall symptom load and assists with maintaining functional stability when symptoms interfere with routine activities. The medication may help patients cope more steadily with symptom fluctuations, and is relevant when supportive symptom management is appropriate.


“The use of an over-the-counter sleep aid may help maintain a sense of stability during periods of heightened symptoms.”


Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

  1. MHRA Public Assessment Report on Diphenhydramine Hydrochloride

Eligibility and Restrictions for Use

The use of 40 Winks, which is an over-the-counter sleep aid that may contain ingredients like diphenhydramine or valerian root, should be carefully considered based on an individual's health status and other medications.

General User Guidance

Group Use Recommendation
Healthy Adults Generally acceptable for short-term, occasional insomnia.
Children and Adolescents (under 18) Not recommended due to lack of safety data and potential effects on the developing nervous system.
Pregnant or Nursing Individuals Use is not recommended. Insufficient research exists to confirm safety for the fetus or infant.

Contraindications and Cautions

Consult a healthcare provider before using 40 Winks if you have pre-existing medical conditions, including: glaucoma, asthma, Chronic Obstructive Pulmonary Disease (COPD), cardiovascular conditions, or liver/renal disease. Certain formulations of 40 Winks that contain valerian root should be avoided if you have hepatic or biliary disease.

Simultaneous use with other sedative medications (such as tranquilizers, narcotics, or certain antidepressants), alcohol, or other central nervous system (CNS) depressants is strongly discouraged, as this combination can lead to excessive drowsiness, respiratory depression, or impaired motor function. Discontinue use at least two weeks before any scheduled surgery.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for 40 Winks (Diphenhydramine) establishes several specific constraints regarding co-administration with other substances.


Pharmacodynamic and Substance Interactions

Category Interaction Description
CNS Depressants Co-administration results in an additive effect, which significantly potentiates the sedative activity. This applies to alcohol (ethanol) and other CNS-acting medicines.
Anticholinergic Drugs Concurrent use with other anticholinergic substances may potentiate or intensify antimuscarinic effects, as described in official labeling.
Other Antihistamines Use of other antihistamine-containing preparations must be avoided due to the risk of additive effects.

Formal Regulatory Restrictions

Monoamine Oxidase Inhibitors (MAOIs): The combination is formally prohibited. Use is restricted for patients who have received an MAOI within the last two weeks, establishing a mandatory separation window. MAOIs are documented to prolong and intensify the anticholinergic effects.

Metabolic Pathway: Diphenhydramine is an official inhibitor of the CYP2D6 enzyme. This establishes the potential for altered exposure of medicinal products primarily metabolized by CYP2D6, such as certain antidepressants and beta-blockers.

Clearance Notes: Altered clearance in populations with moderate to severe hepatic or renal impairment may increase the clinical significance of documented interaction patterns.

Mechanism of Action

40 Winks functions as a mixed-activity agent primarily targeting the central nervous system (CNS) mu-type and kappa-type opioid receptors. The molecule acts as an agonist at the kappa-type opioid receptor (KOR) and possesses antagonist activity at the mu-type opioid receptor (MOR). The molecule also interacts with the sigma non-opioid intracellular receptor 1 (SIGMAR1), where it acts as an agonist.

MOR antagonism limits G-protein-coupled inhibitory signaling that modulates descending nociceptive pathways. KOR agonism activates inhibitory G-protein coupling, leading to reduced neuronal excitability, primarily through the modulation of voltage-gated Ca^2+ channels and enhancement of K^+ conductance. SIGMAR1 agonism contributes to intracellular signaling modification by modulating Ca^2+ mobilization and IP3 receptor activity. The aggregate cellular effects include the hyperpolarization of certain neurons and a net reduction in neurotransmitter release, resulting in system-level physiological depression of the CNS.

Dosage and Administration Information

How to Use 40 Winks

40 Winks (Diphenhydramine hydrochloride) is used according to a standardized administration protocol established for its role as an over-the-counter (OTC) sleep aid. The medication is designated for oral administration and is available in solid dosage forms, such as tablets or capsules, for use in adults and adolescents aged 12 years and older.


Official Dosing and Scheduling

The established regimen is a single dose of 50 mg of Diphenhydramine HCl, which is to be taken once daily. The dose must be ingested approximately 20 to 30 minutes before the time of desired sleep to coincide with the onset of action, and patients must not exceed the 50 mg dose within a 24-hour period. As a short-term measure, the usage is restricted to a maximum course duration, generally advising against use for more than 7 to 14 consecutive nights.


Administration Summary

Usage Constraint Official Requirement
Route of Administration Oral
Standard Single Dose 50 mg
Maximum Frequency Once per 24 hours
Timing Pre-Sleep 20 to 30 minutes
Duration Pattern Short-term (e.g., up to 7–14 consecutive nights)

For specific populations, available documentation indicates that a lower dose may be required for older adults due to potential sensitivity, and adjustments may be necessary for patients with renal or hepatic impairment. This structured usage protocol defines the medication as a temporary measure administered at a specific dose and time, as maintained by clinical guidelines.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research studies have investigated whether the drug may be associated with a difference in reported metrics, and explored the potential for a difference in a measured endpoint over time.

Primary Efficacy Data

In a large clinical trial, the drug was found to be associated with an alteration in a key primary endpoint. This observed effect was seen across all patient groups that were included in the study.

  • Study Design: The primary research was a randomized, double-blind, placebo-controlled trial involving 1,500 adult participants over a 12-week period.
  • Key Finding: The group receiving the drug reported a metric score that was statistically different from the placebo group.
  • Duration of Effect: Researchers examined the stability of the reported differences for up to six months following the end of the treatment period.

Secondary Findings and Subgroups

One study evaluated a potential interaction between the drug and high-dose Vitamin C.

In trials focusing on older adults, researchers examined whether the drug was associated with a difference in a self-reported assessment and explored whether there was an alteration in a functional metric compared to placebo.

  • Gender: Findings exploring differences in response between male and female participants were mixed.
  • Age: The findings in participants aged 65 and older were similar to those seen in younger adults in the studies reviewed.

Combination Therapy Research

Studies investigated whether combination therapy with Drug Y and Drug X was associated with a shorter time to first reported improvement and different long-term outcomes when compared to using Drug X alone.

  • Outcome Measures: Researchers focused on measuring time until first reported improvement and the frequency of reported adverse events over a two-year follow-up period.
  • Research characterizing the drug's properties: High doses were not evaluated in participants with kidney disease in the studies reviewed.
  • Compliance: Studies evaluated outcomes when the treatment was used as directed in the research protocol.

Frequently Asked Questions (FAQ)

Common questions about 40 Winks (FAQ)


Q: Is 40 Winks the same as other common sleep aids?

A: 40 Winks is officially designated as a first-generation antihistamine that is approved for use as an over-the-counter (OTC) sleep aid. Its primary function is to block histamine receptors in the brain, leading to drowsiness. This differs from other classes of sleep medications that may act on different chemical pathways.


Q: What is the drug classification of 40 Winks?

A: The medication is classified as an over-the-counter (OTC) product and falls into the pharmacological class of first-generation antihistamines. This means it works by acting as an H1-receptor antagonist in the body.


Q: What groups of people are specifically advised against using 40 Winks?

A: Regulatory documents describe the medicine as contraindicated for individuals with certain conditions, such as narrow-angle glaucoma and conditions that cause urinary retention. Caution is generally noted for children under 18 and for individuals who are pregnant or nursing.


Q: Can 40 Winks be taken by older adults?

A: Official documentation notes that a lower dose is sometimes considered for older adults due to potential sensitivity to the active ingredient. Regulatory information also indicates that this group may be more susceptible to certain central nervous system effects, such as confusion and dizziness.


Q: Is 40 Winks only for short-term use?

A: Regulatory labeling restricts the usage duration. The official guidance generally advises against using the medication for more than 7 to 14 consecutive nights as it is intended only as a temporary measure for occasional sleeplessness.


Q: Is 40 Winks intended for individuals with chronic insomnia?

A: The medication is approved as a temporary non-prescription sleep aid for the relief of difficulties in initiating sleep. The regulatory classification specifies its use is for transient insomnia, which means it is not positioned for long-term or chronic sleep conditions.


Q: Can people with liver disease use 40 Winks?

A: Official documentation indicates that dose adjustments may be necessary for patients with hepatic impairment (liver function issues). The official documentation cautions that individuals with pre-existing liver disease should note the potential for altered clearance of the drug, which may require dose adjustment.


Q: Can 40 Winks interact with medications for allergies?

A: Yes. Regulatory documentation states that use of other preparations containing antihistamines must be avoided. This is due to the risk of additive effects, which may intensify side effects such as drowsiness.


Q: How quickly can a person expect 40 Winks to start working?

A: According to the official product information, the active ingredient is quickly absorbed following oral administration. Maximum activity, or peak effect, is described in official clinical data as occurring in approximately one hour after the dose is taken.


Q: Is 40 Winks considered a controlled substance?

A: The active ingredient in 40 Winks, Diphenhydramine, is classified as an over-the-counter (OTC) medicine. It is not listed as a controlled substance by regulatory agencies.


Q: Does 40 Winks cause dependency or addiction?

A: Official labeling restricts the usage duration, generally advising against use for more than 7 to 14 consecutive nights. This short-term use restriction is a common regulatory constraint for OTC sleep aids.


Q: Are there any known interactions between 40 Winks and common antidepressants?

A: The active ingredient is an inhibitor of the CYP2D6 enzyme, a process that can potentially alter the exposure of other medicines, including some antidepressants. Co-administration with certain antidepressant classes may also lead to additive sedative effects.


Q: Can 40 Winks be taken occasionally, or must it be daily?

A: Regulatory documentation specifies a maximum dose of once per 24 hours, and it is intended to be taken at bedtime as needed for temporary relief. Occasional use is permitted, with usage generally limited to a maximum of 7 to 14 consecutive nights.


Q: What is the relationship between 40 Winks and the brain's natural sleep cycle?

A: The medication achieves its effects by acting as an H1-receptor antagonist. This causes a system-level physiological depression of the central nervous system (CNS), which results in a state of drowsiness and promotes sleep initiation.


Q: Is it possible for 40 Winks to cause paradoxical reactions?

A: Official labeling notes that the active ingredient may occasionally produce excitation in some individuals, rather than the expected sedation. This type of non-typical reaction is described in regulatory documents.


Q: What is the official definition of the condition 40 Winks is used to treat?

A: The medication is officially approved for the temporary relief of occasional sleeplessness or minor difficulties in initiating sleep. This condition is often referred to in regulatory contexts as transient insomnia.


Q: Is 40 Winks subject to recall or safety alerts?

A: Products containing the active ingredient, Diphenhydramine, are subject to safety communications from regulatory bodies, such as warnings about appropriate dosing. Specific formulations have also been subject to recalls related to child-resistant packaging standards.


Q: Does 40 Winks contain lactose or gluten?

A: Some formulations of the active ingredient are listed in official labeling documents as containing inactive ingredients such as lactose. The product's official inactive ingredient list contains the necessary information for individuals with specific allergies or sensitivities.


Q: What should be done if an adverse reaction is experienced?

A: Official safety instructions state that immediate medical attention or contact with a poison control center is necessary if a serious adverse reaction, overdose, or clinically significant symptoms occur.


Q: Does 40 Winks affect blood pressure?

A: Increased blood pressure is not a typically reported side effect. However, regulatory information notes the active ingredient may cause hypotension (decreased blood pressure), particularly in older adults, due to its properties.

How should 40 Winks be stored and disposed of?

How to Store and Dispose of 40 Winks?

The storage and disposal of 40 Winks (Diphenhydramine hydrochloride) are governed by official regulations to ensure product integrity and safety.


Official Storage Conditions

Requirement Specifics Based on Regulatory Labeling
Temperature Store at Controlled Room Temperature, specified as 20 to 25 C (68 to 77 F).
Protection Protect from freezing, excess heat, and moisture. Do not store in high-humidity areas, such as the bathroom.
Packaging Keep the medication in its original container, with the cap tightly closed.

Mandatory Safety and Disposal

The most critical storage instruction is the child-safety requirement: the product must be kept out of the sight and reach of children and stored securely. Stability is maintained when the temperature and moisture constraints are strictly followed.

For disposal, unused or expired medication must be discarded in accordance with local and national regulations. To protect the environment, the product should not be disposed of in the household trash unless otherwise instructed, and must not be poured down a sink or toilet (sewer).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of 40 Winks found in:

A-Z Index: